Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — doubling your 2.5mg Mounjaro dose is not something you should do on your own. The 2.5mg starting pen exists specifically to let your system adjust to tirzepatide; taking two pens in one week, or injecting twice in a single week, carries real risks that have nothing to do with how motivated you are. If 2.5mg feels like it isn't doing enough, that's the right question to bring to your prescriber — not a reason to reach into the fridge for a second pen. These are prescription-only medicines, and every dose decision requires a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks: "I've been on 2.5mg for a month and barely noticed anything, can I just use two pens?" The frustration is understandable. You signed up expecting change, and the scales are telling you nothing yet.
Here's the reality: the licensed schedule for Mounjaro (tirzepatide) starts at 2.5mg precisely because the first four weeks are not a therapeutic phase at all. They are an acclimatisation period. The gut receptors activated by tirzepatide, both GLP-1 and GIP, respond strongly, and starting lower gives your digestive system time to adjust before the dose does any real work. The NHS patient information for tirzepatide is explicit: 2.5mg is the starting dose only, and titration is what drives results.
That's an important distinction. Patience at this stage isn't a weakness in your approach; it's pharmacologically correct behaviour. Most people who stay on programme see measurable weight change once they move to 5mg and beyond, explore what to expect on 5mg Mounjaro to understand what that transition typically looks like.
Taking two 2.5mg pens in a single week (or injecting on the same day as another dose) is not just outside the licensed schedule. It's a meaningful clinical risk.
The most common consequence is a sharp worsening of gastrointestinal side effects: nausea, vomiting and diarrhoea severe enough to cause dehydration. These effects are dose-dependent, which is exactly why the titration schedule exists. More seriously, in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines. Severe, persistent stomach pain that radiates to the back is a signal to get urgent medical help, not to wait it out. Unsupervised dose increases raise the risk profile without any corresponding clinical benefit, and if you're asking whether a double dose of 2.5mg Mounjaro is ever appropriate, there's no trial evidence that it produces better outcomes than a supervised move to 5mg. If you want a fuller explanation of what doubling the 2.5mg Mounjaro dose actually means in practice, that page works through the question in detail.
There is also a practical problem: Mounjaro pens are single-strength, single-use devices. The 2.5mg pen delivers four weekly doses of 2.5mg. Taking more than one dose from a single pen or using two pens in one week is not how the device is designed, and the SmPC does not support it.
If you've completed your first four weeks and feel ready to move up, the right step is a clinical conversation. At nume, every repeat order and every dose change is reviewed by a GPhC-registered prescriber, a real clinician reading your notes, not software running a check. No dose increase happens without that review, because your prescriber needs to weigh your response, your side-effect history and your current health picture together.
Some people do find 2.5mg genuinely comfortable and move to 5mg at the standard four-week mark. Others need a little longer at the starter dose. Either is normal, and neither is a reason to improvise. If you're curious about what the full titration path looks like from start to maintenance dose, the Mounjaro overview on our treatment page sets it out clearly.
One practical point worth keeping in mind: the pen lives in the fridge, not on the counter. Keeping it refrigerated at 2–8°C between doses matters. If a dose has gone wrong, or you're wondering about timing after a delay, the right reference is your Patient Information Leaflet, or a message to our aftercare team, available seven days a week.
If you're weighing up whether the dose schedule affects cost, the Mounjaro pricing page explains how the different strengths are structured. And if you want to understand whether you can double up on Mounjaro across the full range of strengths, that page covers the question in detail for Mounjaro generally.
Certain situations mean you shouldn't wait for your scheduled review. Contact your clinical team promptly if you experience severe or persistent vomiting, signs of dehydration, severe abdominal pain, or if you've missed a dose and aren't sure how to continue. Our prescribers are reachable through our contact page, and the aftercare line runs seven days a week precisely because these questions don't keep office hours.
The short version: feeling like 2.5mg isn't enough is a signal that titration is working as intended, not a green light to take matters into your own hands. Your prescriber is the person who decides when and how to increase. That's not a bureaucratic obstacle; it's the part of the process that keeps you safe.
If you have more questions about how the dose schedule works in practice, our frequently asked questions cover a range of real-world scenarios, or you can speak to our prescribers directly through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.